Adaptimmune announces commercial development and supply agreement with Thermo Fisher Scientific
Agreement enhances existing Dynabeads CD3/CD28 cell therapy system business
Adaptimmune Therapeutics, a leader in T-cell therapy to treat cancer, has entered into a commercial development and supply agreement with Thermo Fisher Scientific.
The new 10-year agreement augments Adaptimmune's exclusive license and supply relationship with Thermo Fisher for the Dynabeads CD3/CD28 Cell Therapy System (CTS) for use in the manufacture of Adaptimmune's SPEAR T-cell therapies.
Dynabeads CD3/CD28 CTS is designed to isolate, activate and expand human T-cells. This technology provides co-ordinated and simultaneous activation and costimulation signals to T-cells, a process that is reported to produce T-cells with enhanced proliferation and with characteristics that enable prolonged persistence in vivo.
Adaptimmune has an exclusive license for the IP associated with the use of Dynabeads CD3/CD28 to expand and activate all TCR-transduced T-cells in cancer, infectious and autoimmune diseases.
‘We are delighted to expand our collaboration with Thermo Fisher and secure continuity of supply of Dynabeads through commercialisation,’ said Gwen Binder-Scholl, Adaptimmune's Chief Technology Officer. ‘Dynabeads CD3/CD28 have unique properties which we believe optimise the manufacture of our SPEAR T-cell therapies, including the generation of younger and healthier T-cells leading to prolonged persistence of therapeutic cells in the blood. We look forward to continuing to work closely with Thermo Fisher as we progress toward the commercialization of our T-cell therapeutics.’
‘Thermo Fisher's market-leading cell therapy workflow solutions are enabling its customers to address the unique commercialisation challenges of this market. We are pleased to expand our partnership with Adaptimmune, a leader in the T-cell immunotherapy space,’ said Oystein Aamellem, Director of Cellular Medicine for Thermo Fisher. ‘This agreement demonstrates our sustained commitment to advancing the development of our Dynabead CD3/CD28 technology to support the treatment of solid tumors, as well as other conditions that threaten human health.’